Life expectancy of people will increase with the development of new drugs. The Pharmaceuticals Industries are continually playing an excellent role and pushing themselves for delivering high-quality results in patient treatment those coveted profit boundaries while adhering to a burgeoning array of regulatory specifications and additional dynamic forces. Addressing all the essentials of pharmaceutical industries, Spectrum Pharmaceuticals is one such company, expanding patients’ options, offering hope to their patients and making a difference to them by playing a marvelous role in fulfilling this profession.
Spectrum Pharmaceuticals is an American biopharmaceutical company, located in Irvine, California. The company is leading on biotechnology with a specialized focus in Oncology and Hematology, with fully integrated commercial drug development operations. Spectrum Pharmaceuticals is playing an extremely important role to protect the wellbeing of patients in all parts of the world by ensuring quality, proven safety, and efficacy of all the medicinal products.
Dr. Rajesh C. Shrotriya – MD, A Visionary with an Ardent Desire for Success
In September 2000, Dr. Rajesh C. Shrotriya – MD, joined the Company as Chairman and Chief Operating Officer and in August 2002, he was appointed as the Chief Executive Officer. In his tenure, he has spearheaded major changes in the business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals.
Previously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer at SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years, he has held various positions at Bristol-Myers Squibb Company, the most recent being the Executive Director of Worldwide CNS Clinical Research.
Dr. Shrotriya is a 2011 Ernst & Young Orange County Region Entrepreneur of the Year®, award winner. Dr. Shrotriya was specifically cited for his turn-around of Spectrum. The Ernst & Young LLP award program recognizes entrepreneurs who demonstrate excellence and extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Dr. Shrotriya was among the 15 finalists by a panel of independent judges.
Spectrum Pharmaceuticals: Small Company Spirit, Big Company Performance
Spectrum Pharmaceuticals primary strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. In addition to an efficient in-house clinical development, an organization with regulatory and data management capabilities, Spectrum has established a commercial infrastructure for its marketed products.
Currently, Spectrum Pharmaceuticals has six FDA-approved oncology and hematology products on the market that targets different types of non-Hodgkin’s lymphoma, advanced metastatic colorectal cancer, and a type of Acute Lymphoblastic Leukemia (ALL) and multiple myeloma for their patients. Also, Spectrum has their two flagship drugs in late-stage development:
RolontisTM (eflapegrastim), is being developed for chemotherapy-induced neutropenia in patients with breast cancer.
Qapzola™ (apaziquone), is for Intravesical Instillation, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.
Spectrum Pharmaceuticals is having a diversified portfolio of proprietary drugs, including a number that addresses large markets, which could be transformative to the company. These products are in various stages of development, with a focus on oncology and hematology.
“Our passion for identifying, developing and delivering important options for patients suffering from cancer is behind every action we take. At Spectrum, we are committed to excellence and strive to make a difference in the lives of patients every day,” assures Dr. Shrotriya.
Making a difference in the Lives of Patients Every day
Spectrum Pharmaceuticals is redefining cancer care, and their passion is to deliver better options for people who have cancer and it is their prime motive behind every action they take. They work to understand their needs and develop new therapies and supportive care to offer hope for improved disease outcomes and improve the quality of life wherever they can.
“We are committed to conducting all of our actions ethically and with the highest standards. Trustworthiness, honesty, and consistency in our words and actions are considered fundamental to our company’s success,” asserts Dr. Shrotriya.
Delivering the highest quality (safe and effective) products is core to their business. This is an absolute commitment and core competency to be integrated into all of the manufacturing, clinical and regulatory operations. Also, to the best of their abilities, they shall strive to deliver the highest quality: Work output, Communications, and Ongoing service. The company takes great pride in knowing that they stand behind all of their products and work efforts.
Spectrum’s Team: The Best and Brightest Minds Focused on Values
“The Key is our People, and we bring the expertise and passion for excellence of our team to acquire, develop and commercialize pharmaceuticals for unmet medical needs while building value for our shareholders,” says Dr. Shrotriya.
Their strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. Spectrum Pharmaceuticals is establishing a commercial organization for its approved drugs. The company is continuously to building a team with people who have demonstrated skills, passion, commitment and had a track record of success in their areas of focus; while also leveraging the expertise of partners around the world to assist it in the execution of its strategy. Collectively, the members of their team have relevant experience in both the development and marketing of oncology drugs and the growth of profitable business ventures.
Spectrum’s core mission is to bring pharmaceutical products to patients for unmet medical needs. “To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. All of our employees are committed to accomplishing the Company’s mission and living by our corporate values,” affirms Dr. Shrotriya.
After Indian Ministers Fail to Persuade Musk to Incorporate His Tesla Business in India, Musk Has Shifted His Focus to Indonesia
Elon Musk, the CEO of Tesla and SpaceX, is slated to visit Indonesia in November as he wraps up operations...Read more